Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Diabetes health impact fund T1D appoints Elizabeth Mily as CEO

Diabetes health impact fund T1D appoints Elizabeth Mily as CEO

The T1D Fund, an impact investment fund that focuses on solutions to treat, prevent and cure type 1 diabetes, on Wednesday named Elizabeth Mily as CEO. Mily has more than 30 years of pharmaceutical, health-care investment banking, and strategic leadership experience with firms such as Bristol Myers Squibb, Barclays and Goldman Sachs.

“Elizabeth brings a bold strategic vision to the T1D Fund during an exciting period of our evolution. She is the ideal choice to lead the next chapter as we identify and invest in cutting-edge approaches for treating type 1 diabetes,” said Tim Clark, Chair of the Board of Directors at the T1D Fund.

Under Mily’s leadership, the T1D Fund expects to build on its current momentum, growing its investment team and expanding strategic partnerships with an eye toward building an ecosystem for delivering new therapies.

As the T1D Fund’s lead public ambassador, Mily will work to elevate awareness of and investment in leading research, innovation, and the need for cures for type 1 diabetes, the fund said in a press release announcing her appointment.

“The T1D Fund’s unique position as an impact investor enables it to go beyond capital deployment to proactively work with biopharma to bring forward innovative therapies with the potential to translate to transformative cures,” said Mily.

“As someone who knows first-hand the serious impacts the disease has on individuals and their loved ones, I am eager to build upon the team’s meaningful work and partnerships to propel treatments that can improve the lives of those with type 1 diabetes.”

Mily joins the T1D Fund after most recently serving as executive vice president, strategy & business development, at Bristol Myers Squibb BMY , where she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company’s broad equity investing portfolio.

Previously, she held senior roles at Barclays, Thermo Fisher Scientific, and Goldman, Sachs & Co.

The T1D Fund launched in December 2016, it is the first scaled, mission-driven venture impact fund established to catalyze the development of T1D cure-oriented therapies through equity investments in partnership with additional sources of capital, including venture capital, corporations, and foundations.

The fund is a part of Breakthrough T1D, formerly the Juvenile Diabetes Research Foundation, and one of the components of the group’s $100 million “Campaign to Accelerate.

Read more: 5 key pharmaceutical trends that will carry over into 2025

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.